Literature DB >> 2138239

T cells and CD45R expression in B-chronic lymphocytic leukemia.

P G Briggs1, N Kraft, R C Atkins.   

Abstract

A major secondary immunodeficiency exists in B cell derived chronic lymphocytic leukemia (B-CLL) which involves both humoral and cellular immunity and is largely unexplained. Several T cell subset redistributions have been noted in B-CLL. We therefore examined in more detail the immunophenotype of T cells by assessing CD45R expression using a two-colour immunofluorescence technique. The proportion of CD45R+ cells among CD3+, CD4+ and CD8+ cells in B-CLL was significantly (p less than 0.001) higher than in corresponding normal cell populations. We also sought relationships between major T cell subsets and progress of disease and found strongly positive correlations between the total leukocyte count in B-CLL and numbers of CD3+, CD4+, CD8+ cells and monocytes. Further, in patients with clinically more advanced disease, CD3+ and CD4+ cells were present in higher numbers than in patients with less advanced disease (p less than 0.05). CD8+ cells, CD4/CD8 ratio, monocytes and total leukocyte count were not significantly different when comparing the less advanced and more advanced disease patients. An excess of CD45R+ suppressor-inducer T cells has implications for both B and T cell dysfunction and for disease progression.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2138239     DOI: 10.1016/0145-2126(90)90044-a

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease.

Authors:  Shahryar Kiaii; Aniruddha Choudhury; Fariba Mozaffari; Eva Kimby; Anders Osterborg; Håkan Mellstedt
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

2.  The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL).

Authors:  Jennifer A Whitaker; Sameer A Parikh; Tait D Shanafelt; Neil E Kay; Richard B Kennedy; Diane E Grill; Krista M Goergen; Timothy G Call; Saad S Kendarian; Wei Ding; Gregory A Poland
Journal:  Vaccine       Date:  2021-01-16       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.